Skip to main content

Corporate Profile

PrintBio is a privately held, clinical- and commercial-stage biotechnology company and leader in regenerative medicine using novel 3D-bioprinting and material science technologies to deliver safe, functional and personalized products and living tissues and organs, engineered and produced on-demand for patients.  The Company was founded and is led by an experienced team of biotechnology founders and executives.

 

For questions regarding investment opportunities, email: investors@printbio.com

Learn More

Recent Updates

3D Bio Therapeutics Ear

Doctors Transplant Ear of Human Cells, Made by 3-D Printer

| News | No Comments
3DBio Therapeutics, a biotech company in Queens, said it had for the first time used 3-D printing to make a body part with a patent’s own cells. View Full New…
3D Bio Therapeutics Ear

Human Ear Reconstruction Using 3D-Bioprinted Living Tissue Implant in a First-in-Human Clinical Trial

| Press Releases | No Comments
AuriNovo™ an investigational, 3D-bioprinted implant was created using a proprietary process leveraging the patient’s own tissue to generate an implantable ear Phase 1/2a clinical trial enrolling patients with microtia, a…
Human Model Background Image

3DBio Therapeutics Receives FDA Rare Pediatric Disease Designation for AuriNovo™ for Ear Reconstruction in Microtia Patients

| Press Releases | No Comments
NEW YORK, December 6, 2019 /PRNewswire/ — 3DBio Therapeutics, an emerging leader in the field of 3D-bioprinting for human therapeutic use, today announced that the U.S. Food and Drug Administration (FDA) has granted…